Syndax Pharmaceuticals (1T3) Stock Overview
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 1T3 from our risk checks.
1T3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Syndax Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.37 |
| 52 Week High | US$21.66 |
| 52 Week Low | US$10.40 |
| Beta | 0.37 |
| 1 Month Change | -13.91% |
| 3 Month Change | -5.24% |
| 1 Year Change | 62.29% |
| 3 Year Change | 6.53% |
| 5 Year Change | 32.56% |
| Change since IPO | 20.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1T3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.7% | -2.1% | 1.5% |
| 1Y | 62.3% | 7.2% | 3.1% |
Return vs Industry: 1T3 exceeded the German Biotechs industry which returned 7.2% over the past year.
Return vs Market: 1T3 exceeded the German Market which returned 3.1% over the past year.
Price Volatility
| 1T3 volatility | |
|---|---|
| 1T3 Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 1T3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 1T3's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 298 | Michael Metzger | syndax.com |
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor.
Syndax Pharmaceuticals, Inc. Fundamentals Summary
| 1T3 fundamental statistics | |
|---|---|
| Market cap | €1.53b |
| Earnings (TTM) | -€190.92m |
| Revenue (TTM) | €218.15m |
Is 1T3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1T3 income statement (TTM) | |
|---|---|
| Revenue | US$252.25m |
| Cost of Revenue | US$272.45m |
| Gross Profit | -US$20.20m |
| Other Expenses | US$200.57m |
| Earnings | -US$220.76m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.47 |
| Gross Margin | -8.01% |
| Net Profit Margin | -87.52% |
| Debt/Equity Ratio | 3,895.1% |
How did 1T3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/07 00:17 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Syndax Pharmaceuticals, Inc. is covered by 26 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Jason Zemansky | BofA Global Research |